ARCHIVES

NCI Chips In $2 Million For AACR Meeting; Advisors, Senior Staff Not Consulted.

This article is from The Cancer Letter archive.

Vol. 29 No. | August 12, 2003

Download PDF Visit The Full Archive

Related Articles

No Cancer Letter For Next Two Weeks

August 19, 1994

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011

Funding Opportunity: Leukemia & Lymphoma Society Launches Myeloid Program

October 31, 2014

Arzerra Maintenance Therapy Extends PFS In Phase III Trial, Compared to Observation

August 29, 2014

In Brief: Elizabeth Miller Dies; Mihich Names Associate Director At RPMI; AACR Calls For Abstracts

October 23, 1987

Radium-233 Dichloride Increased Overall Survival in Phase III Trial

June 29, 2012